RayKnowChina Research Map
Shortlist

Enrolling by invitationPancreatic cancerN/A

Registered title, quoted from ClinicalTrials.gov

Modified vs Conventional Blumgart Anastomosis of LPD for the Effects of Pancreatic Fistula of Periampullary Carcinoma

An open trial on pancreatic cancer, registered on ClinicalTrials.gov. Led by Affiliated Hospital of Guangdong Medical University; 0 other hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Lead sponsorAffiliated Hospital of Guangdong Medical University广东医科大学附属医院ZhanjiangHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT06076252, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 5

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (5 points)Hide the checklist
  1. 18 years to 75 years; sex: all

    Registered eligibility fields

  2. endoscopic biopsy pathology confirmation of carcinoma (not essential);

    Inclusion criterion 5

  3. preoperative stage within T3N1;

    Inclusion criterion 6

  4. ASA grade IV and / or ECOG physical strength status score> 2 points;

    Exclusion criterion 2

  5. Pregnant or lactating women;

    Exclusion criterion 5

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: earlier treatment; blood tests: counts, liver and kidney function; scans and measurable lesions; other conditions the trial excludes.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT06076252, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

Radically resectable stage I - III low periampullary carcinoma in patients, And all met the following criteria:

  • age 18-75 years;
  • imaging (upper abdominal MRI, MRCP / CT / CTA) diagnosis of periampullary (duodenal papilla, ampulla, inferior common bile duct, pancreatic head);
  • MDT discussion of tumor invasion of large vessels (SMA, CA, CHA/SMV, PV) resectable;
  • endoscopic duodenal ultrasound diagnosis of periampullary carcinoma;
  • endoscopic biopsy pathology confirmation of carcinoma (not essential);
  • preoperative stage within T3N1;
  • no evidence of distant metastasis;
  • cardiopulmonary and liver and kidney function can tolerate surgery;
  • patients and family members can understand and willing to participate in this study, Provided the written informed consent.

Exclusion Criteria:

  • Diagnosis of malignant tumors in other sites;
  • ASA grade IV and / or ECOG physical strength status score> 2 points;
  • Patients with severe liver and kidney function, cardiopulmonary function, coagulation dysfunction or severe basic diseases who cannot tolerate surgery;
  • Have an uncontrolled preoperative infection;
  • Pregnant or lactating women;
  • A history of serious mental illness;
  • Patients with other clinical and laboratory conditions considered by the investigator are not suitable to participate in this trial

Quoted from ClinicalTrials.gov, NCT06076252, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT06076252, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT06076252